In particular, this study addresses the question whether the intranasal administration of NGF-based molecules to Familial Alzheimer Disease-based mouse models might exert neuroprotection and prevent the progression of the neuropathological and behavioral deficits. The gene discussed is NGF; the disease is early-onset autosomal dominant Alzheimer disease.